Brie Carter - Author on Grafa
All
Amazon Pharmacy adds Wegovy oral GLP-1 to platform with low-cost insurance and cash-pay options
Amazon Pharmacy (NASDAQ:AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, now offers Novo Nordisk’s Wegovy® pill, the first and only FDA-approved oral GLP-1 for weight management, through many insurance plans as well as a transparent cash-pay option.
Madrigal Pharmaceuticals secures global rights to Pfizer's ervogastat
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it has entered into an exclusive global license agreement with Pfizer (NYSE:PFE) for ervogastat (formerly PF-06865571), an oral diacylglycerol acyltransferase 2 (DGAT-2) inhibitor currently in Phase 2 development, as well as rights to two additional early-stage metabolic dysfunction-associated steatohepatitis (MASH) assets.
Evolus issues preliminary Q4 and full-year 2025 revenue results
Evolus (NASDAQ:EOLS), a global performance beauty company dedicated to building a differentiated aesthetic portfolio, announced preliminary, unaudited net revenue results for the fourth quarter and full year ended December 31, 2025, along with updated forward-looking guidance.
Aquestive Therapeutics faces FDA-identified deficiencies in Anaphylm NDA
Aquestive Therapeutics (NASDAQ:AQST) reported that the U.S. Food and Drug Administration has identified deficiencies in the new drug application for Anaphylm (dibutepinephrine), an oral sublingual film formulation for the emergency treatment of Type I allergic reactions, including anaphylaxis.
Sanuwave hits record revenue as market turmoil sidesteps UltraMIST
Sanuwave Health (NASDAQ:SNWV) reported preliminary fourth-quarter revenue that reached an all-time high, as the medical device maker effectively navigated a volatile reimbursement landscape that has left many of its competitors in the wound-care sector reeling.
ASE Technology reports strong full-year 2025 revenue growth driven by ATM segment
ASE Technology Holding (NYSE:ASX) reported unaudited consolidated net revenues for December, the fourth quarter, and full year 2025.
December net revenues reached NT$58.865 billion, a 0.1% sequential increase and 11.3% higher year-over-year.










-640x358.jpg&w=1200&q=75)